ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Dongqing YanAnthony D PomicterThomas O'HareMichael W DeiningerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
BCR-ABL1 transcripts at imatinib cessation were quantified by droplet digital PCR (ddPCR) for 175 patients on the STIM2 trial. Patients with BCR-ABL1 transcripts below a defined cutoff had a 12-month molecular recurrence rate of 46% versus 68% for those above the cutoff. Implications of using ddPCR in forecasting successful imatinib cessation are discussed.See related article by Nicolini et al., p. 6606.